New GLP-1 Data Just Changed the Muscle Loss Story

Added: 2026-05-05

[00:00:00]We've been totally wrong about muscle loss on GLP-1 weight loss drugs. Let me catch you up. So, it's become common knowledge that people on weight loss drugs, GLP1 receptors, ompic wobi, drosepide, reatride, lose more lean mass than people who just lose weight via diet and lifestyle alone about 40% versus 25%. But there's a catch that was just clarified in brand new data published in Cell Reports Medicine.

[00:00:24]Basically, the DEXA scans that have been used in the human control trial literature, they cluster together a lot of different tissues and organs as lean mass. So, liver, muscle, and then different components in the muscle all go into one bucket. So, it turns out a lot of the extra lean mass loss that we're seeing in the clinical trials are just things like shrinking livers or your muscles getting rid of substrates it doesn't really need rather than the functional muscle components. In fact, in a proof of principle human trial in the study, they were able to show that while muscle cross-sectional area shrinks in humans on GLP1s, maybe the muscle is just getting rid of stuff it doesn't need, the strength of the muscle doesn't diminish at all in the upper and lower body. Strength is 100% maintained.

[00:01:08]This really reframes how we think about muscle health on these weight loss drugs. This is just level one. If you want to go to level two, three, four, and get the deep nuances, check the long form content and click subscribe to stay uptod date on health